1、 KIM MP, GALLICK GE. Gemcitabine resistance in pancreatic cancer: picking the key players[J]. Clin Cancer Res, 2008, 14(5): 1284-1285. KIM MP, GALLICK GE. Gemcitabine resistance in pancreatic cancer: picking the key players[J]. Clin Cancer Res, 2008, 14(5): 1284-1285.
2、 ANDERSSON R, AHO U, NILSSON BI, et al. Gemcitabine chemoresistance in pancreatic cancer: molecular mechanisms and potential solutions [J]. Scand J Gastroenterol, 2009,44(7): 782-786. ANDERSSON R, AHO U, NILSSON BI, et al. Gemcitabine chemoresistance in pancreatic cancer: molecular mechanisms and potential solutions [J]. Scand J Gastroenterol, 2009,44(7): 782-786.
3、 BERGMAN AM, PINEDO HM, PETERS G J. Determinants of resistance to 2', 2'-difluorodeoxycytidine (gemcitabine)[J]. Drug Resist Updat, 2002, 5(1): 19-33. BERGMAN AM, PINEDO HM, PETERS G J. Determinants of resistance to 2', 2'-difluorodeoxycytidine (gemcitabine)[J]. Drug Resist Updat, 2002, 5(1): 19-33.
4、 MALLINI P, LENNARD T, KIRBY J, et al. Epithelial-tomesenchymal transition: what is the impact on breast cancer stem cells and drug resistance [J]. Cancer Treat Rev, 2014,40(3): 341-348. MALLINI P, LENNARD T, KIRBY J, et al. Epithelial-tomesenchymal transition: what is the impact on breast cancer stem cells and drug resistance [J]. Cancer Treat Rev, 2014,40(3): 341-348.
5、 HAGMANN W, JESNOWSKI R, LOHR JM. Interdependence of gemcitabine treatment, transporter expression, and resistance in human pancreatic carcinoma cells[J]. Neoplasia, 2010, 12(9): 740-747. HAGMANN W, JESNOWSKI R, LOHR JM. Interdependence of gemcitabine treatment, transporter expression, and resistance in human pancreatic carcinoma cells[J]. Neoplasia, 2010, 12(9): 740-747.
6、 SINGH A, SETTLEMAN J. EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer [J]. Oncogene, 2010, 29(34): 4741-4751. SINGH A, SETTLEMAN J. EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer [J]. Oncogene, 2010, 29(34): 4741-4751.
7、 ZHANG J, WANG Z, HU X, et al. Cisplatin and gemcitabine as the first line therapy in metastatic triple negative breast cancer [J]. Int J Cancer, 2015, 136(1): 204-211. ZHANG J, WANG Z, HU X, et al. Cisplatin and gemcitabine as the first line therapy in metastatic triple negative breast cancer [J]. Int J Cancer, 2015, 136(1): 204-211.